INOPP Forum
Pharmacovigilance requirements in Malaysia
Quote from VigiServe Admin on November 27, 2020, 1:24 PMThe pharmacovigilance (PV) system in Malaysia is mature, well-regulated, and harmonized with international standards (e.g., ICH, WHO, and ASEAN frameworks). It is overseen by the National Pharmaceutical Regulatory Agency (NPRA) under the Ministry of Health, which operates as the national regulatory authority for medicines (including biologics and vaccines). The primary legal basis includes the Control of Drugs and Cosmetics Regulations 1984 (Regulation 28 requires immediate reporting of adverse reactions) and supporting guidelines.
Key reference documents (as of late 2025/early 2026):
- Malaysian Guidelines on Good Pharmacovigilance Practices (GVP) for Product Registration Holders (PRHs) — First Edition, August 2021 (with addendum October 2025 or later updates).
- Malaysian Pharmacovigilance Guidelines (2nd Edition, 2016 — foundational, but GVP supersedes for PRHs).
- Drug Registration Guidance Document (DRGD) (latest revisions, e.g., Ninth Revision January 2025) — integrates PV requirements.
- Reporting via MADRAC (Malaysian Adverse Drug Reaction Advisory Committee/NPRA system), with e-reporting tools available.
Legal Framework and Governance NPRA's National Adverse Drug Reaction Monitoring Centre collects ADRs/AEFIs, detects signals, assesses risks, issues alerts/directives, and coordinates with WHO (Malaysia is a long-standing PIDM member, contributing to VigiBase). PRHs (equivalent to MAHs) must maintain a PV system, report safety data, and comply with directives.
Organization and Personnel PRHs must establish/maintain a PV system per GVP guidelines.
- Appoint a responsible person (often a Qualified Person for Pharmacovigilance or equivalent) to oversee activities.
- Pharmacovigilance System Master File (PSMF): Required (new in 2021 GVP, Part 6); describes the PV system in detail. A Pharmacovigilance System Summary (PVSS) provides a brief overview. Submission occurs when requested (e.g., during GVP inspections, voluntary phase 2023–2024 ongoing). PSMF must be maintained/updated and available for inspection.
Individual Case Safety Reports (ICSRs) – Post-Marketing
- PRHs report suspected ADRs/AEFIs to NPRA/MADRAC (via forms, e-reporting, or CIOMS).
- Timelines (per guidelines/Reg 28):
- Serious ADRs (unexpected or expected with increased frequency/severity): Expedited, typically within 15 calendar days of receipt (aligned with ICH).
- Non-serious: Periodic or as required (often within 90 days or in aggregates).
- Foreign ICSRs: Included in periodic reports if relevant to benefit-risk.
Periodic Benefit-Risk Evaluation Reports (PBRER/PSUR)
- PRHs submit PBRERs (ICH E2C(R2) format) to NPRA.
- Frequency: As per GVP (typically every 6 months initially for new products, then annually or longer intervals; specified during registration or on request). Evaluated for benefit-risk appraisal.
Risk Management Plans (RMP)
- Required for certain products (e.g., new chemical entities, high-risk, biologics, or specific concerns).
- Submit RMP (EU-style format preferred) with Malaysia-Specific Annex (MSA) justifying local adaptations.
- Updates required for significant changes or new risks.
Signal Management and Emerging Safety Issues
- PRHs continuously monitor data (global/local) and notify NPRA of validated signals or emerging concerns promptly.
- NPRA handles national signal detection; PRHs support with data submissions.
Clinical Trials-Related Safety Requirements Clinical trials require NPRA approval (Clinical Trial Import Licence/CTIL or Exemption/CTX) per guidelines (e.g., Guideline for Application of CTIL/CTX, Edition 8.1, updated 2025).
- Sponsors monitor safety and report to NPRA.
- Suspected Unexpected Serious Adverse Reactions (SUSARs): Mandatory reporting.
- Malaysian SUSARs (from local sites): Expedited individual reporting (typically 15 calendar days for serious; faster for fatal/life-threatening per ICH E2A norms).
- Non-Malaysian SUSARs: As of April 2025 update, no individual reports required; replaced by six-monthly SUSAR Line Listing (SLL) submissions (aligned with global timelines).
- Development Safety Update Reports (DSURs): Annual/periodic as required (ICH E2F format).
- SAE reporting to ethics committees may be separate. Reports via NPRA channels (forms/email/e-systems); sponsor responsibility for monitoring, assessment, and communication.
Additional Monitoring / Other Aspects
- No black triangle scheme, but additional surveillance possible for high-risk products.
- Voluntary GVP inspections (ongoing program); focus on system compliance.
- Emphasis on ADR/AEFI reporting from HCPs/patients/PRHs; directives for label updates (e.g., RiMUP consumer leaflets).
- Inspections/audits by NPRA; low under-reporting addressed via awareness.
Malaysia's PV framework is robust and ICH-aligned, with structured PRH obligations (including PSMF/PVSS since 2021), expedited serious reporting, and recent clinical trial simplifications (2025). It is more developed than many regional peers. For precise, product- or trial-specific details (e.g., latest addendums, forms, or timelines), consult NPRA directly via npra.gov.my (Pharmacovigilance section, QUEST system, or contacts), as guidelines evolve (e.g., 2025 updates/addendums). Companies operating in Malaysia align with GVP and ICH for compliance.
CONTACT DETAILS
Address:
National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
Phone: +603-7883 5400
Fax: +603-7956 2924, +603-7956 7075
GUIDE MANUAL FOR ADVERSE EVENT REPORTING
The pharmacovigilance (PV) system in Malaysia is mature, well-regulated, and harmonized with international standards (e.g., ICH, WHO, and ASEAN frameworks). It is overseen by the National Pharmaceutical Regulatory Agency (NPRA) under the Ministry of Health, which operates as the national regulatory authority for medicines (including biologics and vaccines). The primary legal basis includes the Control of Drugs and Cosmetics Regulations 1984 (Regulation 28 requires immediate reporting of adverse reactions) and supporting guidelines.
Key reference documents (as of late 2025/early 2026):
- Malaysian Guidelines on Good Pharmacovigilance Practices (GVP) for Product Registration Holders (PRHs) — First Edition, August 2021 (with addendum October 2025 or later updates).
- Malaysian Pharmacovigilance Guidelines (2nd Edition, 2016 — foundational, but GVP supersedes for PRHs).
- Drug Registration Guidance Document (DRGD) (latest revisions, e.g., Ninth Revision January 2025) — integrates PV requirements.
- Reporting via MADRAC (Malaysian Adverse Drug Reaction Advisory Committee/NPRA system), with e-reporting tools available.
Legal Framework and Governance NPRA's National Adverse Drug Reaction Monitoring Centre collects ADRs/AEFIs, detects signals, assesses risks, issues alerts/directives, and coordinates with WHO (Malaysia is a long-standing PIDM member, contributing to VigiBase). PRHs (equivalent to MAHs) must maintain a PV system, report safety data, and comply with directives.
Organization and Personnel PRHs must establish/maintain a PV system per GVP guidelines.
- Appoint a responsible person (often a Qualified Person for Pharmacovigilance or equivalent) to oversee activities.
- Pharmacovigilance System Master File (PSMF): Required (new in 2021 GVP, Part 6); describes the PV system in detail. A Pharmacovigilance System Summary (PVSS) provides a brief overview. Submission occurs when requested (e.g., during GVP inspections, voluntary phase 2023–2024 ongoing). PSMF must be maintained/updated and available for inspection.
Individual Case Safety Reports (ICSRs) – Post-Marketing
- PRHs report suspected ADRs/AEFIs to NPRA/MADRAC (via forms, e-reporting, or CIOMS).
- Timelines (per guidelines/Reg 28):
- Serious ADRs (unexpected or expected with increased frequency/severity): Expedited, typically within 15 calendar days of receipt (aligned with ICH).
- Non-serious: Periodic or as required (often within 90 days or in aggregates).
- Foreign ICSRs: Included in periodic reports if relevant to benefit-risk.
Periodic Benefit-Risk Evaluation Reports (PBRER/PSUR)
- PRHs submit PBRERs (ICH E2C(R2) format) to NPRA.
- Frequency: As per GVP (typically every 6 months initially for new products, then annually or longer intervals; specified during registration or on request). Evaluated for benefit-risk appraisal.
Risk Management Plans (RMP)
- Required for certain products (e.g., new chemical entities, high-risk, biologics, or specific concerns).
- Submit RMP (EU-style format preferred) with Malaysia-Specific Annex (MSA) justifying local adaptations.
- Updates required for significant changes or new risks.
Signal Management and Emerging Safety Issues
- PRHs continuously monitor data (global/local) and notify NPRA of validated signals or emerging concerns promptly.
- NPRA handles national signal detection; PRHs support with data submissions.
Clinical Trials-Related Safety Requirements Clinical trials require NPRA approval (Clinical Trial Import Licence/CTIL or Exemption/CTX) per guidelines (e.g., Guideline for Application of CTIL/CTX, Edition 8.1, updated 2025).
- Sponsors monitor safety and report to NPRA.
- Suspected Unexpected Serious Adverse Reactions (SUSARs): Mandatory reporting.
- Malaysian SUSARs (from local sites): Expedited individual reporting (typically 15 calendar days for serious; faster for fatal/life-threatening per ICH E2A norms).
- Non-Malaysian SUSARs: As of April 2025 update, no individual reports required; replaced by six-monthly SUSAR Line Listing (SLL) submissions (aligned with global timelines).
- Development Safety Update Reports (DSURs): Annual/periodic as required (ICH E2F format).
- SAE reporting to ethics committees may be separate. Reports via NPRA channels (forms/email/e-systems); sponsor responsibility for monitoring, assessment, and communication.
Additional Monitoring / Other Aspects
- No black triangle scheme, but additional surveillance possible for high-risk products.
- Voluntary GVP inspections (ongoing program); focus on system compliance.
- Emphasis on ADR/AEFI reporting from HCPs/patients/PRHs; directives for label updates (e.g., RiMUP consumer leaflets).
- Inspections/audits by NPRA; low under-reporting addressed via awareness.
Malaysia's PV framework is robust and ICH-aligned, with structured PRH obligations (including PSMF/PVSS since 2021), expedited serious reporting, and recent clinical trial simplifications (2025). It is more developed than many regional peers. For precise, product- or trial-specific details (e.g., latest addendums, forms, or timelines), consult NPRA directly via npra.gov.my (Pharmacovigilance section, QUEST system, or contacts), as guidelines evolve (e.g., 2025 updates/addendums). Companies operating in Malaysia align with GVP and ICH for compliance.
CONTACT DETAILS
Address:
National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
Phone: +603-7883 5400
Fax: +603-7956 2924, +603-7956 7075
GUIDE MANUAL FOR ADVERSE EVENT REPORTING